[霍奇金淋巴瘤放化疗疗效的临床评估]

[Clinical evaluation of efficacy of chemoradiotherapy for Hodgkin's disease].

作者信息

Kanaev S V, Gershanovich M L, Pozharisskiĭ K M, Girshovich M M, Malinin A P, Golovanov S G

出版信息

Vopr Onkol. 2004;50(6):652-7.

Abstract

Patients with stage III (A,B) Hodgkin's disease (366) received chemoradiotherapy consisting of 2-4 courses of combined modality treatment followed by total or subtotal irradiation of lymph nodes. Overall 10-year (84%) and 15-year (79%) and relapse-free 10-year (85%) and 15-year (82%) survival was reported in stage IIIA cases. Subtotal exposure proved relatively more effective in such patients without iliac and inguinal lymph node involvement. If, following combined modality therapy, intoxication symptoms were aborted in stage IIIB patients; fairly good results were obtained after total and subtotal irradiation of lymph nodes or involved areas (10-year (70%) and 15-year (65%) overall and 10-year (75%) and 15-year (75%) relapse-free survival.

摘要

III期（A、B）霍奇金淋巴瘤患者（366例）接受了放化疗，包括2 - 4个疗程的综合治疗，随后对淋巴结进行全淋巴结或次全淋巴结照射。据报道，IIIA期病例的10年总生存率为84%、15年总生存率为79%，10年无复发生存率为85%、15年无复发生存率为82%。对于无髂骨和腹股沟淋巴结受累的此类患者，次全照射相对更有效。如果在综合治疗后，IIIB期患者的中毒症状消失，那么在对淋巴结或受累区域进行全淋巴结和次全淋巴结照射后可获得相当好的结果（10年总生存率为70%、15年总生存率为65%，10年无复发生存率为75%、15年无复发生存率为75%）。